Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

Conditions:   Anatomic Stage II Breast Cancer;   Anatomic Stage IIA Breast Cancer;   Anatomic Stage IIB Breast Cancer;   Anatomic Stage III Breast Cancer;   Anatomic Stage IIIA Breast Cancer;   Anatomic Stage IIIB Breast Cancer;   Anatomic Stage IIIC Breast Cancer;   Clinical Stage II Esophageal Adenocarcinoma;   Clinical Stage II Esophageal Squamous Cell Carcinoma;   Clinical Stage II Gastric Cancer;   Clinical Stage II Gastroesophageal Junction Adenocarcinoma;   Clinical Stage IIA Esophageal Adenocarcinoma;   Clinical Stage IIA Gastric Cancer;   Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma;   Clinical Stage IIB Esophageal Adenocarcinoma;   Clinical Stage IIB Gastric Cancer;   Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma;   Clinical Stage III Esophageal Adenocarcinoma;   Clinical Stage III Esophageal Squamous Cell Carcinoma;   Clinical Stage III Gastric Cancer;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma;   Distal Esophagus Squamous Cell Carcinoma;   Esophageal Carcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Limited Stage Small Cell Lung Carcinoma;   Malignant Solid Neoplasm;   Non-Small Cell Lung Carcinoma;   Pancreatic Adenocarcinoma;   Pathologic Stage II Esophageal Adenocarcinoma;   Pathologic Stage II Esophageal Squamous Cell Carcinoma;   Pathologic Stage II Gastric Cancer;   Pathologic Stage II Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IIA Esophageal Adenocarcinoma;   Pathologic Stage IIA Esophageal Squamous Cell Carcinoma;   Pathologic Stage IIA Gastric Cancer;   Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IIB Esophageal Adenocarcinoma;   Pathologic Stage IIB Esophageal Squamous Cell Carcinoma;   Pathologic Stage IIB Gastric Cancer;   Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage III Esophageal Adenocarcinoma;   Pathologic Stage III Esophageal Squamous Cell Carcinoma;   Pathologic Stage III Gastric Cancer;   Pathologic Stage III Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IIIA Esophageal Adenocarcinoma;   Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma;   Pathologic Stage IIIA Gastric Cancer;   Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IIIB Esophageal Adenocarcinoma;   Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma;   Pathologic Stage IIIB Gastric Cancer;   Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IIIC Gastric Cancer;   Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma;   Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma;   Postneoadjuvant Therapy Stage II Gastric Cancer;   Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma;   Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma;   Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma;   Postneoadjuvant Therapy Stage III Gastric Cancer;   Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma;   Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma;   Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma;   Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma;   Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma;   Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma;   Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma;   Progesterone Receptor Negative;   Prognostic Stage II Breast Cancer;   Prognostic Stage IIA Breast Cancer;   Prognostic Stage IIB Breast Cancer;   Prognostic Stage III Breast Cancer;   Prognostic Stage IIIA Breast Cancer;   Prognostic Stage IIIB Breast Cancer;   Prognostic Stage IIIC Breast Cancer;   Stage I Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage II Lung Cancer;   Stage II Pancreatic Cancer;   Stage IIA Lung Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Lung Cancer;   Stage IIB Pancreatic Cancer;   Stage III Lung Cancer;   Stage IIIA Lung Cancer;   Stage IIIB Lung Cancer;   Stage IIIC Lung Cancer;   Triple-Negative Breast Carcinoma
Interventions:   Drug: Ifetroban Sodium;   Other: Placebo
Sponsors:   Vanderbilt-Ingram Cancer Center;   Cumberland Pharmaceuticals
Not yet recruiting

https://ift.tt/2IySZ5f